Format

Send to

Choose Destination
Vaccine. 2009 May 14;27(22):2954-8. doi: 10.1016/j.vaccine.2009.02.106. Epub 2009 Mar 13.

Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.

Author information

1
Division of Vaccine, Statens Serum Institut, Copenhagen, Denmark.

Abstract

Determining incidence rates of potential adverse events before and after an immunisation programme is initiated, provides a useful framework for the evaluation of vaccine safety concerns. Human papillomavirus vaccination (HPV) of adolescent girls has recently been introduced in Denmark. Using a nationwide hospitalisation registry we estimated incidence rates of immune-mediated disorders before HPV vaccination in a cohort of 418,289 Danish girls aged 12-15 years. We further estimated the expected number of cases of immune-mediated disorders occurring in temporal relationship to a hypothetical HPV vaccination schedule purely by chance. Our results and analytical approach provides a framework for the evaluation of adverse event reports following immunisation of adolescent girls.

PMID:
19428906
DOI:
10.1016/j.vaccine.2009.02.106
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center